PRM138
INCREMENTAL IMPROVEMENTS IN ABDALI’S QUALITY OF LIFE (QALY) ANALYSIS IN ABSENCE OF HEAD-TO-HEAD RELATIONSHIP QUALITY OF LIFE (HRQoL) DATA: A CASE STUDY IN THYROID CANCER
Tremblay G1, Lloyd A2, Majhezah U3, Pelletier C, Forsythe A4, Briggs A5
1Essai, Woodiff Lake, NJ, USA, 2Blind Assessment, Oxford, UK, 3Essai Inc, Woodiff Lake, NJ, USA, 4The University of Glasgow, Glasgow, UK

OBJECTIVES: In recent years, the healthcare industry has witnessed a trend for regulatory approvals of innovative technologies in oncology without head-to-head clinical trial evidence or Health Related Quality of Life (HRQoL) data. This yields a challenge to decision-makers who require a cost-effectiveness analysis (CEA) to conduct Health Technology Assessments. To demonstrate methodological approaches and potential data sources to address these gaps, we presented a case study using different health-related quality of life (HRQoL) drugs: lefunavir and sorafenib for management of radioiodine-refractory differentiated thyroid cancer (R-DTC).

METHODS: A vignette study was conducted to elicit utilities for R-DTC health-states and estimate the impact of toxicities on HRQoL makers. 5

RESULTS: Adjusted utilities for lefunavir were estimated as 0.397/0.35 versus 0.351/0.30 for FFS and 0.790/0.45 vs 0.73 OS. FFS (stable) health-state utilities for each drug were adjusted using tumor response rates and incremental utility gain. Combining Phase III toxicity rates and utility decrements yielded a total utility of 0.042 for lefunavir vs. 0.117 for sorafenib. Survival extrapolation (unspecified) provided estimates of increments of 0.66 LYS and 0.50 QALY for lefunavir vs. vs. sorafenib.

CONCLUSIONS: This analysis demonstrates that head-to-head comparisons and patient utility studies and ITC may be used to aid with QALY analysis, especially in orphan diseases where limited data are available. Vignette studies and ITC can increase reliability of comparative effectiveness data and support payers’ decision making.

PRM139
RECOMMENDATIONS FOR ANALYSIS OF PATIENT REPORTED OUTCOMES (PRO) EFFECTIVE DATA WHEN EVALUATING TREATMENT BENEFIT
Nixon MJ, Nixon A
Chilli Consultancy, Salisbury, UK

OBJECTIVES: Lack of rigour in PRO data analysis leads to uncertainty around the quality of life (QoL) improvement and the extent to which conclusions can be drawn from the data. This study sought to provide guidelines for PRO efficacy data analysis for study sponsors in order to ensure confidence in PRO results by stakeholder decision makers. 5

METHODS: A targeted review was undertaken of guidelines for clinical trial and PRO data analysis, and published PRO analysis studies that demonstrated good practice in PRO efficacy analysis. The evidence was synthesised by a team comprising statistical and PRO experts experienced in the analysis of PRO efficacy data. An 8-step guideline was developed based on the available evidence. RESULTS: Eight steps that will ensure high quality analysis of PRO trial efficacy data are (1) avoid unplanned or post analysis by developing a PRO specific SAP prior to data base lock (2) develop a comprehensive PRO data analysis in the clinical trial SAP (3) ensure awareness of differing requirements across stakeholders in PRO data analysis/interpretation and adequately address this in the SAP to ensure (5) specify procedures to address endpoints and a priori approach to confirm item (6) develop and specify appropriate attributes to handling missing data including sensitivity analysis (5) include analysis of PRO score change from baseline (6) specify approaches to interpreting change from baseline data including any baseline which will be applied during interpretation (7) implement a 100% double programming approach alongside table review by statistically qualified team members (8) interpret PRO results not only in isolation but alongside other clinical outcomes. CONCLUSIONS: For PRO data to effectively inform decision making across all stakeholders, high standards of data analysis needs to be mandatory. This 8-step guideline, if adhered to, will raise the standard of PRO data analysis reducing the likelihood that PRO data is discounted by decision makers.

PRM140
MAPPING THE BECK DEPRESSION INVENTORY TO THE EQ-5D-3L IN PATIENTS WITH DEPRESSIVE DISORDERS
Grochottr A1, Betschneider C1, Höyer M2, König H3
1University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 2Technische Universität Dresden, Dresden, Germany

OBJECTIVES: For cost-utility analyses, data on health state utilities, as provided by the EQ-5D-3L, is needed but not always available. This study specifies a mapping algorithm from the Beck Depression Inventory (BDI) index to the EQ-5D-3L index adjusted to account for socio-demographic variables and depressive disorders. METHODS: A sample of 1,074 consecutive patients with depressive disorders from a psychotherapeutic outpatient clinic was included in the study. Standardized clinical questionnaires were applied to establish relevant diagnoses. For the mapping of the EQ-5D-3L index from the BDI index and selected patient socio-demographic characteristics, ordinal least squares regression with robust standard errors was used. Model prediction properties were tested using the root mean squared error and a leave one out cross validation of the sampling process. The challenge was to predict the EQ-5D-3L index with a significant proportion of variance explained. The highest model goodness of fit was estimated for models with the BDI index and age as independent variables. The root mean squared error of the predicted EQ-5D-3L index in the validation samples ranged from 0.225 to 0.228 between the models. CONCLUSIONS: The specified mapping algorithms from the BDI index to the EQ-5D-3L index for patients with depressive disorders are acceptable for usage as approximation in cost-utility analyses. Further validation in independent samples is necessary to obtain more confidence in their performance.

PRM141
ISSUES AFFECTING QUALITY OF LIFE AND DISEASE BURDEN IN LIPOPROTEIN LIPOSE DEFICIENCY (LPLD) – FIRST STEP TOWARDS A PRO MEASURE IN LPLD
Johnson C1, Stroes ES2, Soran H3, Wierzbicki A4, Moulin P5, Bruckert E6, Ossenkoppele B10, Steinhausen-Thiessen E5, Gaudet D7, Gotti J8, Rastellitti F9, Omenkoppoyle B9, Dippel M10, Leclerc M11, Arvenda M12
1University Hospital Southampton, Southampton, UK, 2Department of Vascular Medicine, Amsterdam Medical Center, Amsterdam, The Netherlands, 3Cardiovascular Trials Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK, 4Gy’s & St. Thomas’ Hospitals, London, UK, 5Department of Endocrinology, CarMeN – Research Laboratory in Cardiometabolic Disease, Jönköping, Sweden, 6Policlinico Salpêtrière – Charles Foix, Paris, France, 7Interdisciplinary Metabolism Center, Charité, University of Berlin, Berlin, Germany, 8Community Genome Medicine Centre and Lipid Clinic, University of Montpellier, Cizicou, QC, Canada, 9Chiesi Farmaceutici, Parma, Italy, 10unitec B & V, Amsterdam, The Netherlands

OBJECTIVES: LPLD is an ultra-orphan genetic lipid disorder (prevalence 1-2/million) that is associated with severe hypertriglyceridemia and an increased risk of acute pancreatitis. Other manifestations include eruptive xanthoma, fatigue, difficulty with concentrating and cardiopulmonary symptoms. Associated symptoms, combined with the high cost of the disorder (Quality-adjusted life-year) only justify support for the disease-specific measure exists to assess QOL and the burden of LPLD. As part of post approval commitment of alipogene tiparozovary, regulatory bodies requested the development of a QLQ in LPLD. We present the process of exist-5

METHODS: To develop a disease-specific questionnaire, we included 5 patients from four countries assessed the relevance and importance of each item of the three questionnaires. Patients’ ratings were discussed during an in-depth, face-to-face interview and the disease burden questionnaire was comprehensively discussed, analyzed and then modified where necessary. RESULTS: Quantitative assessment showed that 25 (45%) of the QLQ-C30 and QLQ-PAN26 questions were relevant to the majority of patients. The most relevant items were pain (6), fatigue and sleeping problems (4), digestive and dietary factors (4), work, daily and social activity restrictions (4) and impact on emotional functioning (3). Qualitative and quantitative analysis of the new questionnaire highlighted the unpredictability of pancreatitis attacks and the impact of the strict low fat diet on social and emotional factors. Less common clinical manifestations were included with the exception of acute pancreatitis as approximation in cost-utility analyses. A further validation in independent sam-5

ple was necessary to obtain more confidence in their performance.

PRM142
INTERNAL STRUCTURE OF THE MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE
Bilbao A1, Escober A2, Gorostiza F1, Garcia-Perez I2, Navarro Q3, Quirós R4
1Basurto University Hospital (Osakidetza) - REDISSE, Bilbao, Spain, 2Dirección del Servicio de Salud de la Región de Murcia - REDISSE, Murcia, Spain, 3Instituto Clínic Sabadell, Barcelona, Spain, 4Casta del Sol Hospital - REDISSE, Maribella - Malaga, Spain

OBJECTIVES: The Minnesota Living with Heart Failure Questionnaire (MLHFQ) is one of the most widely used health-related quality of life (HRQoL) specific questionnaires for patients with heart failure (HF). It provides two dimensions (physical and emotional) and a global score. However, there are some concerns about its factor structure, and different alternatives have been proposed, including even a third factor representing a social dimension. The objective of the present study was to study the internal structure of the MLHFQ, the unidimensionality of the total score, and to compare the different factor structures raised. METHODS: We included 2565 patients hospitalized for HF, who were provided with the MLHFQ during hospitalization. The structural validity of the questionnaire was studied by confirmatory factor analysis (CFA) for categorical data, and the Rasch rating scale model. These two approaches were also applied to the different structures proposed. RESULTS: The results of the CFA for the hypothesized model of two latent factors and the Rasch analysis confirmed the adequacy of the physical and emotional dimensions. We only found two problematic items within the total score. The results of the CFA applied to other two-factor structures proposed were not better than the results of the original structural. The Rasch analysis applied to the different social factors showed the best results for Munyombwe’s social dimension. CONCLUSIONS: The results support the validity of using the MLHFQ physical and emotional subscales in patients with HF, as well as the total score. In addition, the results confirmed the existence of a third social factor, and we recommend the use of Munyombwe’s social factor.

PRM143
IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES FOLLOWING 52 WEEKS OF TREATMENT WITH CERTOZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN DMARD-NAIVE PATIENTS WITH SEVERE, ACTIVE, ASYMMETRIC, RHEUMATOID ARTHRITIS: RESULTS FROM THE C-EARLY RANDOMIZED, DOUBLE-BLIND, CONTROLLED PHASE 3 STUDY
Emsley F1, Bingham C2, Burnetser G3, Bykerk V4, Furst D5, Mariette X7, Pacoraro O6, Coteur O4, Vanlaeth M8, Weill-Mathis A
1University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 2Technische Universität Dresden, Dresden, Germany

OBJECTIVES: The current GLA-31 index for patients with depressive disorders is not suitable for usage as approximation in cost-utility analyses. Further validation in independent samples is necessary to obtain more confidence in their performance.